Research Areas

Overarching interests of the Stripp Laboratory are to define epithelial stem and progenitor cells that maintain the human lung, and to define mechanisms that regulate quiescence versus activation of these reparative cells and renewal versus differentiation in the setting of normal tissue maintenance and lung disease. Studies in the Stripp Lab benefit from the participation of patients receiving clinical care for lung disease who generously provide access to clinical samples that are used to identify candidate cellular and molecular targets for initiation and progression of chronic lung disease. Three-dimensional culture systems and genetically defined animal models are used to define mechanisms of disease and validate therapeutic targets.

Structural Remodeling of the Lung in Chronic Lung Disease


Lung tissue remodeling, suboptimal repair leading to loss of structure and function, is pathognomonic of most chronic lung diseases and accounts for progressive declines in lung function, morbidity and mortality. Chronic diseases of small airways and the gas-exchange region have an enormous societal impact both within the U.S. and worldwide. Of the estimated 225,000 deaths attributed to lung disease in the U.S. in 2007, greater than 50 percent were due to chronic obstructive pulmonary disease (COPD). Less prevalent but with more limited treatment options is idiopathic pulmonary fibrosis (IPF), the most common type of interstitial pneumonia, which has a mean survival time of three years after initial diagnosis and afflicts upward of 0.2 percent of the population in North America and Europe.

Chronic Obstructive Lung Disease


Stripp Lab research seeks to establish preclinical mouse models of COPD to understand basic mechanisms that drive initiation and progression of disease and for validation of candidate therapies.

Cystic Fibrosis


Cystic fibrosis (CF) is a monogenic disorder affecting approximately 1 in 2,500 births or an estimated 70,000 individuals worldwide. The underlying genetic defect involves mutations that affect functionality of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to defects in electrolyte transport. The most pronounced clinical manifestations of CF result either from epithelial dysfunction and mucus plugging in many different tissues, including the upper and lower respiratory tracts, gastrointestinal tract and reproductive tract, or from defects in nutrient and salt absorption/secretion. The advent of novel pharmacologic approaches to modulate CFTR trafficking or function has provided effective therapeutic options for approximately 75 percent of patients. However, improved options that go beyond palliative therapy are desperately needed for the thousands of patients who are not responsive to CFTR modulator therapy. Our goals are to provide an improved understanding of epithelial defects observed in lungs of patients with CF lung disease and to develop stem cell replacement therapies aimed at providing treatment options to patients who are not responsive to current drug therapies.

Lung Cancer


Lung cancer remains the leading cause of cancer-related deaths both nationally and worldwide. Of lung cancer cases, non-small cell lung cancers (NSCLC) are the most prevalent, with adenocarcinoma and squamous cell carcinoma accounting for 85 percent of all NSCLC cases. Adenocarcinomas include a rage of overlapping subhistotypes that collectively represent the most common subtype of NSCLC. A pervasive problem in the treatment of all cancers is their ability to undergo somatic mutations leading to the generation of a heterogeneous population of tumor cells, each of which has the potential to show unique profiles of sensitivity to commonly used chemotherapeutic drugs.

Non-Small Cell Lung Cancer


Cystic fibrosis (CF) is a monogenic disorder affecting approximately 1 in 2,500 births or an estimated 70,000 individuals worldwide. The underlying genetic defect involves mutations that affect functionality of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to defects in electrolyte transport. The most pronounced clinical manifestations of CF result either from epithelial dysfunction and mucus plugging in many different tissues, including the upper and lower respiratory tracts, gastrointestinal tract and reproductive tract, or from defects in nutrient and salt absorption/secretion. The advent of novel pharmacologic approaches to modulate CFTR trafficking or function has provided effective therapeutic options for approximately 75 percent of patients. However, improved options that go beyond palliative therapy are desperately needed for the thousands of patients who are not responsive to CFTR modulator therapy. Our goals are to provide an improved understanding of epithelial defects observed in lungs of patients with CF lung disease and to develop stem cell replacement therapies aimed at providing treatment options to patients who are not responsive to current drug therapies.

Influenza Virus–Induced Lung Injury


Influenza virus infection has the potential to causes widespread epithelial cell injury and lung tissue damage, the extent of which is highly dependent on viral strain and host susceptibility (e.g., age, pregnancy). Pandemic H1N1 influenza A virus causes particularly severe lung injury, which is associated with morbidity and in some cases mortality among infected individuals. Stripp Lab studies use a mouse-adapted strain of H1N1 influenza virus that causes tissue damage and structural lung remodeling in infected mice. Goals of our research are to define epithelial stem and progenitor cells that are activated to repair damaged lung tissue following viral infection and to understand how activation of innate immune signaling regulates stem cell fate.

Contact the Stripp Lab

127 S. San Vicente Blvd.
Advanced Health Sciences Pavilion, Room A8600
Los Angeles, CA 90048